PFS and correlative biomarker analysis from coBRIM study of cobimetinib plus vemurafenib in advanced BRAF-mutated melanoma | Dr Paolo Ascierto at Annual Meeting 2015 - 101271

Spotlight
Video

PFS and correlative biomarker analysis from coBRIM study of cobimetinib plus vemurafenib in advanced BRAF-mutated melanoma | Dr Paolo Ascierto at Annual Meeting 2015

EMJ has 458 videos Subscribe Here

Loading........
Description: At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Paolo A. Ascierto, MD, of Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Naples, Italy, discusses the median progression-free survival (PFS) evaluation and correlative biomarker analysis from coBRIM, a phase 3 study of cobimetinib plus vemurafenib in patients with advanced BRAF-mutated melanoma.

–––

European Medical Journal

Website: http://emjreviews.com/...
Twitter: https://twitter.com/EMJRevi...
Facebook: https://www.facebook.com/em...
Shared By : EMJ
Posted on : 07/20/15
Added : 3 years ago



Recommended

Nothing found.

More From EMJ

Nothing found.